title: [Propranolol for the treatment of severe hemangiomas of infancy: results from a series of 28 patients].
abstract: OBJECTIVE
  Recent reports have described the successful use of propranolol to treat severe hemangiomas of infancy. The few case series that have been reported, however, have included only a small number of patients. The aim of this study was to describe the results of oral propranolol treatment for severe hemangiomas of infancy in terms of treatment outcome and the occurrence of adverse events.
  
  
  METHODS
  A descriptive, observational study was undertaken in a series of children with severe hemangiomas of infancy seen in the pediatric dermatology unit at Hospital Universitario Virgen del Rocío in Seville, Spain between July 2008 and December 2009. Patients were included if they had hemangiomas in the proliferative phase or involuting lesions with substantial residual deformity. All children were treated with oral propranolol (2 mg/kg/d) and followed until September 2010. Epidemiologic characteristics were analyzed along with treatment response at 3, 6, 9, 12, and 18 months; adverse events were also recorded at those times.
  
  
  RESULTS
  Thirty-six hemangiomas were treated in 28 patients. Propranolol treatment was effective in all cases, with a good or complete response in 88.2% at 6 months. Effects were apparent within a few hours of treatment, which was effective in both growing and involuting hemangiomas. In ulcerated hemangiomas, the mean healing time was 61 days. Adverse events were mild and self-limiting. Only 2 patients discontinued treatment due to hypotension.
  
  
  CONCLUSIONS
  In the majority of cases, oral propranolol produced rapid and sustained improvements in hemangiomas of infancy and shortened the natural course of the disease with few side effects. However, no significant reductions in symptoms or healing time were observed in ulcerated hemangiomas.
authors.affiliation: Unidad de Dermatología Pediátrica, Hospitales Universitarios Virgen del Rocío, Sevilla, España. jbernabeuw@gmail.com
authors.forename: J
authors.initials: J
authors.lastname: Bernabeu-Wittel
authors.forename: J J
authors.initials: JJ
authors.lastname: Pereyra-Rodríguez
authors.forename: M E
authors.initials: ME
authors.lastname: Mantrana-Bermejo
authors.forename: I
authors.initials: I
authors.lastname: Fernández-Pineda
authors.forename: J C
authors.initials: JC
authors.lastname: de Agustín
authors.forename: J
authors.initials: J
authors.lastname: Conejo-Mir
mesh_terms: D000284:Administration, Oral; D002675:Child, Preschool; D005260:Female; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D011433:Propranolol / Q000008:administration & dosage*; D012720:Severity of Illness Index; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D011433:Propranolol